Category: New products
-
Cancer Immune System Therapy Start-Up Raises $53M
A company developing treatments that retune the immune system to kill solid tumor and blood-related cancers is raising $53 million in its first venture funding.
-
FDA Grants Emergency Clearance for Home Covid-19 Test
The Food and Drug Administration gave an emergency authorization for a self-collected Covid-19 diagnostic test, the first such test for home use.
-
$500K Challenge Seeks A.I. Covid-19 Reopening Models
A new challenge from XPrize seeks evidence-based models using artificial intelligence to help governments reopen their economies during the pandemic.
-
ALS Stem Cell Therapy Fails to Meet Trial Objective
Clinical trial results of an amyotrophic lateral sclerosis, or ALS, therapy do not show slower disease progression among patients compared to a placebo.
-
Blood Cells Transport Enzymes to Slow Cancer Spread
Researchers devised a technique that in lab mice carries immune system enzymes on red blood cells to stop the spread of cancer in the lungs.
-
Covid-19 Vaccine Shown Effective, Temperature-Stable
Interim clinical trial results show the Moderna Covid-19 vaccine prevents infection in 94 percent of cases and can stored for 30 days in normal refrigeration.
-
Tech, Genomics Companies Form DNA Storage Alliance
Four companies from the computer technology and genomics industries are starting a coalition to advance DNA as a data storage medium.
-
Covid-19 Saliva Test Earns FDA Emergency Clearance
A test to detect Covid-19 viruses in saliva rather than nasal swabs received emergency authorization from Food and Drug Administration.
-
Personal Cancer Vaccine Induces Tumor Shrinkage
Interim results from a clinical trial show some head and neck cancer patients receiving a personalized vaccine and immunotherapy report tumor shrinkage.
-
Coronavirus Antibody Maker Raises $80M in New Funds
A company developing synthetic antibodies to protect against a range of coronavirus infections, including Covid-19, is raising $80 million in new venture funds.